Therapeutic effect of pramipexole hydrochloride combined with levodopa/benserazide on Parkinson disease and its influence on levels of serum-related factors
Therapeutic effect of pramipexole hydrochloride combined with levodopa/benserazide on Parkinson disease and its influence on levels of serum-related factors
刘兴梅 1赵俊涵 1尹小妹 2黄云艳 1袁峰 1张丽红
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 临沂市中医医院神经内科，临沂 276000
2. 临沂市中医医院内分泌科，临沂 276000
折叠
摘要
目的 探究盐酸普拉克索联合多巴丝肼治疗帕金森病(PD)的效果及对血清相关因子水平的影响。 方法 队列研究。抽取2022年6月至2023年6月临沂市中医医院收治的68例PD患者，按照随机数字表法分为对照组和研究组，每组34例。对照组给予多巴丝肼治疗，研究组给予普拉克索联合多巴丝肼治疗。比较两组的治疗有效率，比较两组治疗前后认知功能[简易智力状态检查量表(MMSE)评分]、运动功能[帕金森病统一评分量表(UPDRS)]、血清相关因子[脑源性神经营养因子(BDNF)、5－羟色胺(5－HT)、去甲肾上腺素(NE)、胰岛素样生长因子1(IGF－1)、同型半胱氨酸(Hcy)]水平，比较两组不良反应发生情况。 结果 研究组治疗有效率(97.06%，33/34)高于对照组(82.35%，28/34)，P<0.05。治疗后，两组MMSE各项评分及总分均高于治疗前，且研究组高于对照组(P<0.05)。治疗后，两组UPDRS Ⅱ、UPDRS Ⅲ、UPDRS Ⅳ评分及总分均低于治疗前，且研究组低于对照组(P<0.05)。治疗后，两组BDNF、5－HT、NE、IGF－1水平均高于治疗前，Hcy水平低于治疗前，且研究组BDNF、5－HT、NE、IGF－1水平高于对照组，Hcy水平低于对照组(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。 结论 盐酸普拉克索与多巴丝肼联合治疗，能够改善PD患者的认知功能，减轻运动障碍并调节血清相关因子水平，能够提高治疗有效率，且安全性高。 Objective To analyze the efficacy of pramipexole hydrochloride combined levodopa/benserazide in the treatment of Parkinson disease (PD), and to investigate its influence on levels of serum-related factors. Methods A total of 68 patients with PD treated in Linyi Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were selected for the cohort study, and they were divided into a control group and a study group by random number table method, with 34 cases in each group. The control group was treated with levodopa/benserazide, and the study group was treated with pramipexole combined with levodopa/benserazide. The effective rates of the two groups were compared. The cognitive function assessed by mini-mental state examination (MMSE), motor function assessed by unified Parkinson’s disease rating scale (UPDRS), levels of serum-related factors, including brain derived neurotrophic factor (BDNF), 5-hydroxytryptamine (5-HT), norepinephrine (NE), insulin-like growth factor 1 (IGF-1) and homocysteine (Hcy) were compared between the two groups before and after treatment. The incidences of adverse reactions of the two groups were compared. Results The total effective rate of the study group was 97.06% (33/34), higher than the 82.35% (28/34) of the control group (P<0.05). After treatment, the each item score and total score of MMSE in both groups were higher than those before treatment, and the scores in the study group were higher than those in the control group (P<0.05). After treatment, the UPDRS Ⅱ, UPDRS Ⅲ, UPDRS Ⅳ scores and total scores in both groups were lower than those before treatment, moreover, the UPDRS Ⅱ, UPDRS Ⅲ, UPDRS Ⅳ scores and total scores in the study group were lower than those in the control group (P<0.05). After treatment, the levels of BDNF, 5-HT, NE, and IGF-1 in both groups were higher than before treatment, while the Hcy level was lower than that before treatment (P<0.05) in addition, the levels of BDNF, 5-HT, NE, and IGF-1 in the study group were higher than those in the control group, while the Hcy level was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions The combination of pramipexole hydrochloride and levodopa/benserazide can improve the cognitive function of PD patients, reduce dyskinesia and regulate the levels of serum-related factors, which can improve the treatment efficiency, with high safety.
Abstract
Objective To analyze the efficacy of pramipexole hydrochloride combined levodopa/benserazide in the treatment of Parkinson disease (PD), and to investigate its influence on levels of serum-related factors. Methods A total of 68 patients with PD treated in Linyi Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were selected for the cohort study, and they were divided into a control group and a study group by random number table method, with 34 cases in each group. The control group was treated with levodopa/benserazide, and the study group was treated with pramipexole combined with levodopa/benserazide. The effective rates of the two groups were compared. The cognitive function assessed by mini-mental state examination (MMSE), motor function assessed by unified Parkinson’s disease rating scale (UPDRS), levels of serum-related factors, including brain derived neurotrophic factor (BDNF), 5-hydroxytryptamine (5-HT), norepinephrine (NE), insulin-like growth factor 1 (IGF-1) and homocysteine (Hcy) were compared between the two groups before and after treatment. The incidences of adverse reactions of the two groups were compared. Results The total effective rate of the study group was 97.06% (33/34), higher than the 82.35% (28/34) of the control group (P<0.05). After treatment, the each item score and total score of MMSE in both groups were higher than those before treatment, and the scores in the study group were higher than those in the control group (P<0.05). After treatment, the UPDRS Ⅱ, UPDRS Ⅲ, UPDRS Ⅳ scores and total scores in both groups were lower than those before treatment, moreover, the UPDRS Ⅱ, UPDRS Ⅲ, UPDRS Ⅳ scores and total scores in the study group were lower than those in the control group (P<0.05). After treatment, the levels of BDNF, 5-HT, NE, and IGF-1 in both groups were higher than before treatment, while the Hcy level was lower than that before treatment (P<0.05) in addition, the levels of BDNF, 5-HT, NE, and IGF-1 in the study group were higher than those in the control group, while the Hcy level was lower than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions The combination of pramipexole hydrochloride and levodopa/benserazide can improve the cognitive function of PD patients, reduce dyskinesia and regulate the levels of serum-related factors, which can improve the treatment efficiency, with high safety.
万方数据